tiprankstipranks
Trending News
More News >
Vor Biopharma, Inc. (VOR)
:VOR
US Market

Vor Biopharma (VOR) AI Stock Analysis

Compare
832 Followers

Top Page

VO

Vor Biopharma

(NASDAQ:VOR)

Rating:33Underperform
Price Target:
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
Positive Factors
Product Approval
Telitacicept has been successful in the clinic and has received marketing approvals in China for multiple conditions.
Strategic Partnerships
Vor announced an exclusive license agreement with RemeGen Co., Ltd to develop and commercialize telitacicept in ex-Greater China geographies.
Negative Factors
Financial and Strategic Uncertainty
Despite having a healthy balance sheet, the uncertainties due to potential strategic alternatives have led to a downgrade of VOR stock to Neutral from Buy.
Operational Challenges
The company is winding down all clinical and manufacturing operations, retaining only eight essential employees, leading to a workforce reduction of approximately 95%.

Vor Biopharma (VOR) vs. SPDR S&P 500 ETF (SPY)

Vor Biopharma Business Overview & Revenue Model

Company DescriptionVor Biopharma (VOR) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat cancer. The company is pioneering the development of engineered hematopoietic stem cells (eHSCs) to enable targeted cancer therapies while reducing off-target toxicity. Vor Biopharma aims to transform the treatment landscape for patients with hematologic malignancies by utilizing its proprietary technology to enhance the therapeutic index of anticancer agents.
How the Company Makes MoneyVor Biopharma generates revenue primarily through research and development collaborations, partnerships, and potential future product sales. The company's business model is centered around developing its pipeline of eHSC-based therapies, which are designed to improve the efficacy and safety of existing cancer treatments. Revenue streams may include milestone payments and royalties from strategic partnerships with larger pharmaceutical companies, as well as potential licensing agreements for its proprietary technologies. Additionally, Vor Biopharma may secure funding through government grants or research institutions to support its innovative research initiatives.

Vor Biopharma Financial Statement Overview

Summary
Vor Biopharma demonstrates significant financial strain, with no revenue generation and consistent net losses. The company's balance sheet shows declining equity, and cash flow statements reflect ongoing cash burn problems. These factors collectively point to high financial risk and uncertainty about future viability.
Income Statement
10
Very Negative
Vor Biopharma has consistently reported zero revenue, indicating a lack of operational income generation. The company has been operating at a loss for several years, with negative EBIT and net income, highlighting significant profitability challenges.
Balance Sheet
35
Negative
The company maintains a moderate debt-to-equity ratio, which suggests limited leverage. However, the continuous decline in stockholders' equity and total assets since 2020 raises concerns about financial stability and sustainability.
Cash Flow
20
Very Negative
Vor Biopharma's free cash flow has been consistently negative, indicating cash burn issues. The operating cash flow is also negative, suggesting operational inefficiencies and an inability to cover costs without external funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-900.00K0.00-3.49M-8.96M-4.45M-1.39M
EBITDA-120.43M-113.39M-114.37M-90.89M-67.58M-41.95M
Net Income-118.60M-116.91M-117.86M-90.77M-68.78M-43.34M
Balance Sheet
Total Assets109.31M142.89M198.13M299.37M242.59M75.91M
Cash, Cash Equivalents and Short-Term Investments60.03M91.93M137.18M230.25M207.47M48.54M
Total Debt30.78M31.83M35.66M38.91M18.01M18.29M
Total Liabilities43.24M46.23M47.40M48.76M26.33M27.64M
Stockholders Equity66.07M96.66M150.72M250.61M216.26M48.27M
Cash Flow
Free Cash Flow-100.61M-99.89M-101.36M-93.61M-73.04M-40.45M
Operating Cash Flow-100.26M-99.66M-100.29M-85.14M-69.14M-36.29M
Investing Cash Flow52.65M96.86M71.01M-94.09M-91.65M-4.16M
Financing Cash Flow52.69M53.39M2.94M117.14M232.91M82.53M

Vor Biopharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.45
Price Trends
50DMA
0.43
Positive
100DMA
0.68
Positive
200DMA
0.83
Positive
Market Momentum
MACD
0.27
Negative
RSI
82.22
Negative
STOCH
75.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Positive. The current price of 1.45 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.43, and above the 200-day MA of 0.83, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 82.22 is Negative, neither overbought nor oversold. The STOCH value of 75.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VOR.

Vor Biopharma Risk Analysis

Vor Biopharma disclosed 81 risk factors in its most recent earnings report. Vor Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Vor Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
49
Neutral
$87.58M149.62%-18.22%44.67%
47
Neutral
$107.22M-45.55%98.56%37.97%
47
Neutral
$57.64M-116.63%-100.00%24.59%
46
Neutral
$89.22M-59.45%48.92%
46
Neutral
C$194.85M-4.28-8.56%2.84%13.52%-1.74%
37
Underperform
$71.82M-63.22%-100.00%-26.44%
VOVOR
33
Underperform
$181.19M-125.43%2.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VOR
Vor Biopharma
1.45
0.54
59.34%
ZNTL
Zentalis Pharmaceuticals
1.24
-2.38
-65.75%
PLRX
Pliant Therapeutics
1.20
-9.32
-88.59%
CCCC
C4 Therapeutics
1.52
-3.00
-66.37%
ELUT
Aziyo Biologics
2.16
-2.41
-52.74%
SNTI
Senti Biosciences
2.21
-1.13
-33.83%

Vor Biopharma Corporate Events

Executive/Board Changes
Vor Biopharma’s Chief Medical Officer Resigns
Neutral
Apr 3, 2025

On March 31, 2025, Eyal C. Attar, M.D., announced his resignation as Chief Medical Officer of Vor Biopharma Inc., effective April 18, 2025, to pursue a new opportunity. Vor Biopharma plans to enter into a consulting agreement with Dr. Attar for transition services, acknowledging his contributions to the company.

Business Operations and Strategy
Vor Biopharma Approves Stock Option Repricing Strategy
Neutral
Feb 6, 2025

On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025